The manufacture, marketing and supply of medicinal cannabis products raise complex regulatory issues in the jurisdiction where those activities take place. These go beyond the issues applicable to medicines in general, even some whose potential harms are far greater. John Binns and David Hardstaff at BCL Solicitors LLP explain how new opportunities for investment will help further drive developments and growth in a sector that promises significant potential gains for patients in need.